John J McCabe insider trades: Eleven Biotherapeutics (EBIO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 14, 2017 | EBIO | ↓ Sell | 1,399 | $2.10 | $3K | Direct | Feb 16, 2017 (2d) |
| Aug 15, 2016 | EBIO | ↓ Sell | 1,170 | $4.80 | $6K | Direct | Aug 17, 2016 (2d) |
| Feb 16, 2016 | EBIO | ↓ Sell | 1,501 | $0.27 | $405 | Direct | Feb 17, 2016 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About John J McCabe's insider trades
John J McCabe is Chief Financial Officer at Eleven Biotherapeutics (EBIO). Since Feb 16, 2016, John has reported no open-market purchases and 3 sales worth $9K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (11 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.